Helicobacter pylori surface and enzymes

Helicobacter pylori surface and enzymes represent a collective group of bacterial proteins essential for the survival and pathogenesis of H. pylori in the human stomach (StatPearls, 2023). The enzyme urease is a primary target, as it neutralizes gastric acid to facilitate colonization (PubMed, PMID: 21248321). Surface adhesins like BabA and SabA mediate attachment to the gastric epithelium, while virulence factors such as CagA and VacA induce host cell damage (Nature Reviews Microbiology, 2006). Therapeutic strategies target these components using antibiotics like amoxicillin and clarithromycin to inhibit cell wall and protein synthesis, respectively, often in combination with bismuth salts that inhibit bacterial enzymes (Mayo Clinic, 2023). Eradication of these targets is the standard of care for treating peptic ulcers and preventing gastric cancer (NIH, 2022).

Other names

H. pylori antigensHelicobacter pylori virulence factorsH. pylori proteomeHelicobacter pylori surface proteins

Drugs targeting H. pylori surface and enzymes function by inhibiting essential bacterial processes: beta-lactams (e.g., amoxicillin) inhibit cell wall synthesis; macrolides (e.g., clarithromycin) and tetracyclines inhibit protein synthesis; nitroimidazoles (e.g., metronidazole) disrupt DNA; and bismuth salts provide multi-targeted inhibition of bacterial enzymes and adherence (StatPearls, 2023; Mayo Clinic, 2023).